Next-Gen Miniaturized, Leadless Pacemakers Offer Longer Battery Life and Easier Programming
By HospiMedica International staff writers Posted on 02 May 2023 |
Heart block, also known as atrioventricular (AV) block, is a condition where the electrical signals between the heart's chambers (the atria and the ventricles) are disrupted. Historically, patients with AV block have been treated with conventional dual-chamber pacemakers, which are implanted in the upper chest, beneath the skin below the collarbone, and connected to the heart with thin wires called "leads." Over their roughly 60-year history, pacemakers have seen significant advancements, including miniaturization, improvements in pacing technology, MRI compatibility, and remote monitoring. Now, the latest generation of industry-leading miniaturized, leadless pacemakers offers a 40% longer battery life than their predecessors, along with numerous other benefits.
Micra AV2 and Micra VR2, the world's smallest pacemakers, from Medtronic plc (Dublin, Ireland) provide approximately 40% more battery life and easier programming than previous Micra pacemakers while retaining the many advantages of leadless pacing, such as reduced complications compared to traditional pacemakers. Similar in size to a multivitamin, Micra pacemakers are less than one-tenth the size of conventional pacemakers. Micra pacemakers eliminate the need for leads or a surgical "pocket" under the skin, thereby removing potential sources of complications related to leads and pockets, and leaving no visible indication of the device.
The Micra AV2 and Micra VR2 boast approximately 40% more battery life compared to previous generations, with a median projected battery life of nearly 16 and 17 years, respectively. This means that over 80% of patients who receive the pacemaker are expected to only need one device for life. The new Micra AV2 also features advanced algorithms that automatically program AV synchrony, thereby coordinating the heart's upper and lower chambers. Additionally, for active patients, the Micra AV2 offers a higher available tracking capability for faster heart rates (increased from 115 to 135 beats per minute for upper limits).
"Our goal is to improve the patient experience by continuously reinventing our ground-breaking leadless pacemaker," said Robert C. Kowal, M.D., Ph.D., general manager, Cardiac Pacing Therapies within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Since inventing the first battery-operated cardiac pacemakers 65 years ago, Medtronic has transformed pacing technologies to benefit patients, including the nearly 200,000 patients globally who have received a Micra device so far."
Related Links:
Medtronic plc
Latest Critical Care News
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis
- World's First AI-Powered Sepsis Alert System Detects Sepsis in One Minute
- Smartphone Magnetometer Uses Magnetized Hydrogel to Measure Biomarkers for Disease Diagnosis
- New Technology to Revolutionize Valvular Heart Disease Care